Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY OUTCOMES) trial results confirmed the effectiveness and safety of PCSK9 inhibitors compared with placebo using alirocumab, another PCSK9 inhibitor. Here, PCSK9 is linked to acute coronary syndrome.